Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash from Financing Activities: 2018-2025

Historic Cash from Financing Activities for Whitehawk Therapeutics (WHWK) over the last 5 years, with Jun 2025 value amounting to -$850,000.

  • Whitehawk Therapeutics' Cash from Financing Activities fell 1077.01% to -$850,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $94.5 million, marking a year-over-year increase of 115132.93%. This contributed to the annual value of $130,000 for FY2024, which is 60.12% down from last year.
  • According to the latest figures from Q2 2025, Whitehawk Therapeutics' Cash from Financing Activities is -$850,000, which was down 100.89% from $95.2 million recorded in Q1 2025.
  • In the past 5 years, Whitehawk Therapeutics' Cash from Financing Activities registered a high of $141.7 million during Q3 2021, and its lowest value of -$850,000 during Q2 2025.
  • Moreover, its 3-year median value for Cash from Financing Activities was $53,000 (2024), whereas its average is $10.5 million.
  • Within the past 5 years, the most significant YoY rise in Whitehawk Therapeutics' Cash from Financing Activities was 952,110.00% (2025), while the steepest drop was 1,077.01% (2025).
  • Whitehawk Therapeutics' Cash from Financing Activities (Quarterly) stood at $88,000 in 2021, then tumbled by 221.59% to -$107,000 in 2022, then surged by 174.77% to $80,000 in 2023, then crashed by 33.75% to $53,000 in 2024, then tumbled by 1,077.01% to -$850,000 in 2025.
  • Its Cash from Financing Activities stands at -$850,000 for Q2 2025, versus $95.2 million for Q1 2025 and $53,000 for Q4 2024.